Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment (PERFECT)
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment (PERFECT Study)
The purpose of this study is to evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) affects survival in patients with inoperable pancreatic carcinoma. By using a prospective single-arm design with historical controls, this study aims to generate clinically relevant data while minimizing the number of patients exposed to experimental treatment. The findings may support future integration of EUS-RFA into standard care for this high-need patient population.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Clara Søndersted, MD
- Telefoonnummer: 45 38683868
- E-mail: clara.theodora.soendersted@regionh.dk
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult habile patients with a signed informed consent
- Histologically confirmed pancreatic carcinoma ≤5 cm in largest diameter
- ECOG performance status 0-2
- Patients not eligible for curative-intended surgical treatment due to:
Advanced (unresectable) disease, or Unsuitability for surgery due to comorbidities or poor performance status, or Patient preference to decline surgery
Exclusion Criteria:
- Metastatic disease
- Uncorrected coagulopathy (INR ≥1.5 or thrombocyte count < 50 mia/L)
- Altered anatomy or interposition of major vessels precluding safe EUS-RFA
- Active untreated infection or pancreatitis
- Life expectancy <3 months
- Prior local ablative treatment interfering with outcome
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: EUS-RFA plus standard oncological treatment
Participants receive endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using a 19G RFA needle (EUSRA, STARMed, Gyeonggi-do, South Korea) connected to an RF generator, as a supplement to standard palliative oncological treatment. EUS-RFA is performed under deep sedation or general anesthesia and may be repeated at approximately 4-week intervals contingent on patient condition. All participants continue standard oncological follow-up, including systemic therapy and regular cross-sectional imaging, in parallel with the study intervention. |
A 19G RFA needle (EUSRA, STARMed, Gyeonggi-do, South Korea) is introduced through the working channel of an echoendoscope and advanced into the pancreatic tumor under real-time ultrasound guidance. The needle is connected to a dedicated RF generator delivering a current of 400-500 kHz, which induces coagulative necrosis in the targeted tissue. Treatment is continued until complete ablation is confirmed ultrasonographically, or until an impedance value of 800 Ω is reached, at which point the generator automatically terminates power output to limit further tissue damage. A cooling pump circulates chilled saline through the needle to reduce charring at the ablation site. The procedure is performed transgastrically or transduodenally under deep sedation or general anesthesia, and may involve one or more ablation cycles per session. Treatment may be repeated at approximately 4-week intervals, depending on radiological response and patient tolerance.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival
Tijdsspanne: From index date until death from any cause, assessed up to 4 years
|
Time from index date (first day of systemic oncological therapy or first visit at the Department of Oncology (for patients who do not receive systemic therapy)) to death from any cause. Participants alive at the time of last follow-up will be censored at that date. |
From index date until death from any cause, assessed up to 4 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression- and metastatic-free survival
Tijdsspanne: From index date until progression, metastasis, or last follow-up, assessed up to approximately 4 years
|
Time from index date to radiological progression of the primary tumor or development of distant metastases, assessed according to RECIST 1.1 on cross-sectional imaging. |
From index date until progression, metastasis, or last follow-up, assessed up to approximately 4 years
|
|
Local tumor control at 6 and 12 months
Tijdsspanne: At 6 and 12 months after index date
|
Proportion of participants with local tumor control (absence of local progression) on cross-sectional imaging at 6 and 12 months, assessed according to RECIST 1.1. |
At 6 and 12 months after index date
|
|
Procedure-related adverse events
Tijdsspanne: At 30 days after each EUS-RFA procedure
|
Adverse events occurring within 30 days of each EUS-RFA treatment, graded according to the AGREE classification. |
At 30 days after each EUS-RFA procedure
|
|
Time to biliary/duodenal intervention
Tijdsspanne: From index date until intervention or last follow-up, assessed up to approximately 4 years
|
Time from index date to first biliary or duodenal intervention (e.g., stenting) |
From index date until intervention or last follow-up, assessed up to approximately 4 years
|
|
Pain score change compared to baseline
Tijdsspanne: Baseline and at 6, 12 and 18 months after inclusion
|
Change from baseline in pain severity, measured using a Numeric Rating Scale (NRS, 0-10) |
Baseline and at 6, 12 and 18 months after inclusion
|
|
Opioid consumption change compared to baseline
Tijdsspanne: Baseline and at 6, 12 and 18 months after inclusion
|
Change in opioid consumption, converted to total daily oral morphine milligram equivalent (MME). |
Baseline and at 6, 12 and 18 months after inclusion
|
|
Quality of Life change compared to baseline (EORTC QLQ-C30)
Tijdsspanne: Baseline and at 6, 12 and 18 months
|
Change from baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Global Health Status/Quality of Life scale, ranging from 0 (worst) to 100 (best), with higher scores indicating better quality of life. |
Baseline and at 6, 12 and 18 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Bojan Kovacevic, MD, PhD, Herlev Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 16-0302-148
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .